PP
VRCA icon

PDT Partners’s Verrica Pharmaceuticals VRCA Stock Holding History

PDT Partners’s Portfolio VRCA Stock Details VRCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-1,080
Closed -$99K – 1136
2021
Q4 		$99K Buy
+1,080
New +$122K 0.01% 822
2021
Q3 		– Sell
-1,620
Closed -$183K – 926
2021
Q2 		$183K Buy
+1,620
New +$196K 0.01% 720

Other funds holding VRCA

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kornitzer Capital Management Shawnee Mission, Kansas $4.79B AUM 30.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FI
Fosun International Hong Kong, China $446M AUM 13.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

PDT Partners's VRCA Position: Q1 2022 in Review

PDT Partners sold out of Verrica Pharmaceuticals (VRCA) in Q1 2022, closing a stake of 1,080 shares — an estimated $99K sold.

PDT Partners first reported a position in VRCA in Q2 2021 and held it in 2 quarters. The position peaked at $183K in Q2 2021. 51 funds tracked by Wall St. Rank hold VRCA as of Q1 2022.

  • PDT Partners reported no remaining Verrica Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • PDT Partners sold 1,080 Verrica Pharmaceuticals shares in Q1 2022, an estimated $99K.
  • PDT Partners first reported a position in Verrica Pharmaceuticals in Q2 2021 and held it in 2 quarters.
  • PDT Partners's Verrica Pharmaceuticals position peaked at $183K in Q2 2021.
  • 51 funds tracked by Wall St. Rank held Verrica Pharmaceuticals as of Q1 2022.

Based on PDT Partners's 13F filing for Q1 2022, filed 16 May 2022.